Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Blood–Brain Barrier in Non-Human Primates with PET

Authors:

Abstract
[18F]MC225 has been developed as a weak substrate of P-glycoprotein (P-gp) aimed to measure changes in the P-gp function at the blood-brain barrier (BBB) with positron emission tomography (PET). This study evaluates [18F]MC225 kinetics in non-human primates and investigates the effect of both scan duration and P-gp inhibition. Three rhesus monkeys underwent two 91-min dynamic scans with blood sampling at baseline and after P-gp inhibition (8mg/kg tariquidar). Data were analyzed using 1-Tissue-Compartment Model (1-TCM) and 2-Tissue-Compartment Model (2-TCM) fits using metabolite-corrected plasma as input function, and for various scan durations (10-, 20-, 30-, 60- and 91-min). The preferred model was chosen according to the Akaike Information Criterion (AIC) and the standard errors (SE%) of the estimated parameters. For the 91-min scan duration, the influx constant K1 increased by 40.7% and the volume of distribution (VT) by 30.4% after P-gp inhibition, while the efflux constant k2 did not change significantly. Similar changes were found for all evaluated scan durations. K1 did not depend on scan duration (10-min-K1=0.2191 vs 91-min-K1=0.2258), while VT and k2 did. 10-min scan duration seems sufficient to properly evaluate the P-gp function using K1 obtained with 1-TCM. For 91-min scan, VT and K1 can be estimated with a 2-TCM and both parameters can be used to assess P-gp function.

This publication has 44 references indexed in Scilit: